Journal
TRANSPLANTATION
Volume 85, Issue 2, Pages 163-165Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0b013e3181609054
Keywords
pharmacogenetics; immunosuppression; tacrolimus; CYP3A5; transplantation
Categories
Ask authors/readers for more resources
Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is essential to prevent rejection. The most attractive candidate for a pharmacogenetic strategy is tacrolimus dosing based on the CYP3A5 genotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available